slow_feet
4 years ago
8-K: 2/1/21
Item 1.01 Entry Into a Material Definitive Agreement.
As previously disclosed, Adamas Pharma, LLC, a wholly-owned subsidiary of Adamas Pharmaceuticals, Inc. (the βCompanyβ) is involved in a lawsuit against Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA), Inc. (collectively βZydusβ) in the United States District Court for the District of New Jersey alleging infringement of the Companyβs patents by Zydus. On January 30, 2021, the Company entered into a definitive agreement (the βDefinitive Agreementβ) with Zydus pursuant to which the parties agreed to end the lawsuit and dismiss it without prejudice. Pursuant to the Definitive Agreement, the Company grants a license to make, use, sell, offer to sell and import a generic version of GOCOVRI® (amantadine) extended release capsules, effective as of March 4, 2030, or earlier in certain circumstances typical for such agreements. In addition, the Definitive Agreement contains provisions that may accelerate the license date, including if unit sales of GOCOVRI in the 12-month period ending July 31, 2025 or any subsequent 12-month period decline by a specified percentage below GOCOVRI unit sales in the year ended December 31, 2019.
The Definitive Agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice. The Company expects to file the Definitive Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2021.
Zydus Pharmaceuticals
TFMG
4 years ago
$ADMS | #AdamasPharmaceuticals Upside Targets
Adamas Pharmaceuticals , Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
whytestocks
5 years ago
News: $ADMS ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, May 31, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS ) f...
Find out more https://marketwirenews.com/news-releases/ongoing-investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-adamas-pharmaceuticals-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-8278320.html